Rossum raises record $100 million Series A from General Catalyst to reinvent B2B document communication
Rossum, the artificial intelligence company that is re-inventing the way businesses send documents to each other, has raised $100m from one of the US’s best known funds, General Catalyst in what is Eastern Europe’s largest ever Series A. Previous investors, including LocalGlobe, Seedcamp, Miton and Elad Gil are participating, as Rossum looks to capitalise on surging corporate demand for automation in business processes.
Having rapidly secured market leadership in document AI technology and become the go-to software for many of Europe’s biggest companies, Rossum is creating a universal document gateway designed to help the corporate world move faster and complete transactions in minutes not weeks. Rossum’s founders, three PhD students who dropped out of university to start the business, are automating the whole business communication stack with a view to making bureaucratic, costly and time-consuming document communication frictionless and paperless.
Rossum has seen year-on-year growth of five times in the last 12 months, as established businesses and startups have woken up to the impact that Robotic Process Automation can make to their productivity and resourcing. The company’s vision of making B2B document communication frictionless, forever, has strongly resonated with businesses large and small who use the AI-based B2B platform to exchange and process all sorts of documents, seamlessly, without overhauling the existing infrastructure of email and PDF documents.
Corporate appetite for automation soars
Over 150 of Europe’s biggest and fastest growing companies including Bosch, Siemens, Veolia, EY and Adyen are using the platform to exchange and process documents such as invoices, purchase orders, quotations, financial statements and customs declarations. The cloud-based document gateway frees up human teams from onerous data entry work, links all related documents in a transaction, keeps transactions on timetable with automated data flows and integrates documents with other enterprises systems, including SAP and Oracle.
While enterprise RPA focuses on internal processes, Rossum is pioneering the automation of cross-company processes - something that was immensely challenging without advanced AI technology. Enabling the flow of documentation between companies frees up a massive amount of manpower, which has previously been devoted to tedious and soul-destroying manual document processing. Rossum estimates that its systems save its users typically over 90% of the manual work.
The $100 million funding will be used to hire more high skill engineering and AI talent at Rossum, which is seeing particularly strong demand for its products in North America, Western Europe and the Asia Pacific region. The funds will also be used to open new company hubs in the US, Europe and Asia and plans to open a research center in Prague, dedicated to B2B document communication, in co-operation with Czech universities.
Single unified enterprise solution
Rossum is investing heavily in product development, demonstrating that its AI technology leadership can apply to a wide range of use cases. While its mission of frictionless AI-enabled data capture remains central to Rossum’s software, the company is gradually automating the whole business communication stack, creating a single unified enterprise solution for communication between businesses.
The next stage of Rossum’s journey will see it expand its product and partner ecosystem around specific verticals including finance, logistics, insurance and order management. It is establishing a universal document gateway capable of handling the whole range of processes and document types of each industry. Processes from fraud detection at the start of a transaction, to approvals at the end will be built into the platform’s workflows.
“There is a hidden opportunity in the fact that every single product in the world requires hundreds of companies to cooperate, and that produces thousands of transactions. As market leaders in document AI technology, we are in a unique position to transform the way these transactions are communicated and processed. Rossum already saved billions of keystrokes in data entry for our clients. Now we are saving people’s time across the whole process of transaction handling by building an end-to-end business communication platform. Businesses large and small are waking up to the huge gains that they will make from such a system and they trust us to deliver it,” Tomas Gogar, Rossum’s CEO, said.
“Rossum spotted a problem that is so ubiquitous that we rarely even think about it. The founders realized the massive hidden opportunity, and created a disruptive solution based on an entirely new deep technology. Rossum is still early on its journey, but it has already grown into a company with worldwide reach that has had a tremendous impact on global enterprise customers,” said Trevor Oelschig, Managing Director at General Catalyst.
“It is remarkable that three AI scientists from Prague dropped out from academia to start a business and five years later they are leading a company of 140, serving some of the world’s top brands and building something exceptional. The storylines of lightning speed growth like UiPath, Celonis and now Rossum show how the CEE region is becoming a true global powerhouse of AI and Automation. Again and again, we see the combination of great business ambition and deep technical skill from this region,” said Reshma Sohoni, founding partner at Seedcamp.
“Rossum is on the cusp of an enormous market opportunity. Documents of all forms are the lifeblood of business-to-business communication, and every company in the world will want to automate this process sooner or later and Rossum is perfectly positioned to meet this need. Its world-leading AI technology for cognitive data capture means that Rossum adopters do not need to coordinate with their business partners to automate this communication,” said Mish Mashkautsan, General Partner, at LocalGlobe and Latitude.
Founded in 2016 by AI PhD students Tomas Gogar, Petr Baudis and Tomas Tunys who dropped out of university to start the business, all three were named among Financial Times' New Europe 100 Challengers and Gogar was named in Forbes' 30 under 30 list. Baudis’ PhD work is also credited in Google’s scientific paper on its historic AlphaGo AI victory in 2016.
Rossum has previously raised $9.5M in total and the existing investors also participate in the current round. Rossum’s customers include Cushman & Wakefield, BDO, Suez and PwC, while its technology is embedded in modern business technology providers such as Celonis or Flexport.
Rossum has been named one of the most promising European cloud companies in the Accel Euroscape two years in a row, and listed in the CB Insights' annual selection of the 100 most promising private AI companies in the world. Everest Group rated Rossum a ‘Star Performer’ for 2020 with regards to its market impact in the document processing space.
Customer quotes:
Jana Vlkova, Head of Accounts Payable, PepsiCo, CEE, said: "We had a never-ending backlog before we implemented Rossum. Now, we can always complete our work on time."
Michal Cipa, IT Manager , Cosco Shipping Line, said: “All our invoices are going through Rossum; I can’t imagine our paperless AP process functioning without it.”
- End -
About Rossum
Rossum is eliminating useless paperwork by automating business communication. Thousands of lifetimes per day are burned on manually dealing with documents in enterprise back offices - it’s a terrible job, and it makes the whole world go slower. Rossum’s proprietary AI engine outranks narrow data extraction solutions in accuracy and saves its users typically over 90% of the manual work. Rossum serves hundreds of the world’s best companies ranging from business software vendors like Celonis to Fortune 500 class enterprises such as Bosch, Cushman & Wakefield, COSCO Shipping, Delivery Hero, Deloitte, EY, K+S, Molson Coors, PepsiCo, Siemens, Suez and Veolia. Rossum is funded by the top venture capital funds in London and the most experienced Silicon Valley angels and has already saved over five billion keystrokes globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005884/en/
Contact information
Aimee Soulsby
Aimee@burlington.cc
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
